The specificity of poliovirus encapsidation has been studied using a novel chimeric genome in which the gene encoding firefly luciferase has been substituted for the VP2±VP3±VP1 genes of the poliovirus capsid (P1) gene. Transfection of RNA transcribed in vitro from this genome resulted in a VP4-luciferase fusion protein which retained luciferase enzyme activity. Since the detection of enzyme activity was dependent upon replication of the transfected RNA genome, we refer to these genomes as replicons. The replicon encoding luciferase was encapsidated upon transfection of the genomic RNA into cells previously infected with a recombinant vaccinia virus, VV-P1, which encodes the poliovirus type 1 capsid proteins (P1). Infection of cells with each serial passage, followed by analysis of luciferase enzyme activity, revealed that encapsidated replicons could be detected at the first passage with VV-P1. Amplification of the titer of encapsidated replicons occurred upon serial passage with VV-P1, as evidenced by the high expression levels of luciferase enzyme activity following infection. Serial passage of the luciferase replicons with poliovirus type 1, 2, or 3 resulted in the trans encapsidation into the type 1, 2, or 3 capsids, respectively. In contrast, serial passage with bovine enterovirus, Coxsackievirus A21 or B3, or enterovirus 70 did not result in trans encapsidation, even though co-infection of cells with the replicon and different enteroviruses resulted in high-level expression of luciferase. The results of this study highlight the specificity of poliovirus encapsidation and point to the use of encapsidated replicons encoding luciferase as a reagent for dissecting elements of replication and encapsidation.
INTRODUCTION
Picornaviruses are small, plus-strand RNA viruses which include the enteroviruses (poliovirus, bovine enterovirus, Coxsackieviruses, and enterovirus 70), rhinoviruses, cardioviruses, and apthoviruses (Koch and Koch, 1985) . Picornavirus virions contain a single-stranded RNA genome of approximately 7500 bp in length. Upon infection of cells, the viral genome is translated into a single polyprotein which is processed by virally encoded proteases to generate the viral proteins (Kitamura et al., 1981; Semler et al., 1981) . This long single polyprotein is functionally divided into three distinct regions: P1 encodes the capsid or structural proteins, while P2 and P3 encode the nonstructural or replication proteins. An initial cleavage of the polyprotein between the P1 and P2 regions is catalyzed by the 2A protease (2A pro ) and occurs cotranslationally at a tyrosine±glycine amino acid pair (Nicklin et al., 1986 (Nicklin et al., , 1987 Toyoda et al., 1987) . Subsequent cleavages of the P2 and P3 region are catalyzed by the protease 3C pro at glutamine±glycine amino acid pairs. Cleavage of the P1 protein occurs in trans by the 3CD protein, which is a fusion between 3C pro and 3D pol , the viral polymerase (Kuhn and Wimmer, 1987; Harris et al., 1990; Palmenberg, 1990) . The development of an infectious cDNA clone for poliovirus facilitated studies to delineate the role of viral proteins and regions of the genome in replication (Kitamura et al., 1981; Racaniello and Baltimore, 1981) . Early studies from Kaplan and Racaniello demonstrated that regions of the P1 gene could be deleted without compromising the capacity of the RNA to undergo self-replication (Kaplan and Racaniello, 1988) . Follow-up studies demonstrated that insertion of foreign genes into the P1 region resulted in expression as long as the translational reading frame was maintained between the foreign gene and the poliovirus P2 and P3 regions. Previous studies from this laboratory have described the construction of self-replicating genomes, termed replicons, which encode the nonstructural proteins of poliovirus downstream from a foreign gene substituted for the P1 region (Porter et al., 1993 (Porter et al., , 1996 (Porter et al., , 1997 Ansardi et al., 1994; Moldoveanu et al., 1995; Anderson et al., 1996a,b) . The transfection of the replicon RNA into cells resulted in replication and expression of the gene substituted for the P1 region.
Although the details of the mechanism and specificity of poliovirus encapsidation are not known, early studies identified poliovirus genomes which contained deletions in the P1 gene that could be encapsidated if serially passaged in the presence of wild-type poliovirus (Cole et al., 1971; Cole and Baltimore, 1973a,b,c; Cole, 1975) . These RNAs acted as defective interfering genomes (DI). Further analysis of DI genomes revealed that the majority of the deletions occurred in the VP2±VP3±VP1 genes of the P1 region (Nomoto et al., 1975) . Percy et al. (1992) constructed a replicon which contained the gene encoding chloramphenicol acetyltransferase (CAT) substituted for VP4, VP2, and part of the VP3 genes. Transfection of this RNA into cells followed by infection with wild-type poliovirus resulted in the encapsidation of the replicon encoding CAT. A detailed analysis of the encapsidation of this replicon, though, was complicated by the presence of the wild-type helper virus in these preparations which prevented the isolation and characterization of a homogeneous population of encapsidated replicons. We have demonstrated that transfection of replicon RNAs into cells previously infected with a recombinant vaccinia virus which expresses P1 (VV-P1) resulted in the encapsidation of the RNA by the P1 protein provided in trans. Serial passage of the encapsidated replicon in the presence of VV-P1 resulted in the generation of stocks of the encapsidated replicons.
Previous studies from this laboratory have described the construction and characterization of encapsidated replicons encoding foreign proteins. Although immunoprecipitation was used to detect the encapsidated replicons, this technique was not sensitive enough for detailed analysis of poliovirus replication and encapsidation. In the present study, we have generated encapsidated replicons which encode the firefly luciferase marker protein. We demonstrate that infection of cells with this replicon results in the production of enzymatically active luciferase protein. The level of luciferase detected from cells infected with the encapsidated replicons correlated with the infectious dose. Co-infection of cells with this replicon and other picornaviruses was used to analyze replication, as well as to examine the specificity of RNA encapsidation. The results of these studies are discussed with respect to the use of this novel replicon as a means of dissecting and characterizing features of poliovirus replication and encapsidation.
RESULTS

Construction of a replicon encoding luciferase
Previous studies from this laboratory have characterized the expression of foreign proteins from poliovirusbased replicon genomes. In these studies, the complete HIV-1 Pr55 gag gene sequences were substituted for either the entire P1 coding region or for the VP2, VP3, and VP1 coding sequences . Upon serial passage of in vitro transcribed RNA from each replicon with VV-P1, a difference in the levels of encapsidated RNA was detected. These results suggested that although the VP4 capsid sequences are not required for encapsidation, the presence of the VP4 gene sequences might affect the efficiency of encapsidation. Based on these results, we constructed replicons encoding the luciferase gene substituted for the VP2±VP3±VP1 capsid sequences, which maintains the VP4 capsid gene sequences positioned 5Ј to the luciferase gene sequences.
In order to subclone the luciferase gene, the poliovirus cDNA pT7-IC was modified to contain a unique XhoI restriction site between the VP4 and VP2 capsid genes (Fig. 1A) . Since poliovirus is translated as a single polyprotein which is subsequently processed to generate mature proteins, a unique SnaBI restriction site was introduced at nucleotide 3359, followed by coding se- quences for 8 amino acids constituting a cleavage site for the 2A protease: Thr-Lys-Asp-Leu-Thr-Thr-Tyr-Gly (cleavage site underlined). To construct the replicon pT7-Luc, PCR was used to amplify a 1.7-kb gene encoding luciferase (nucleotides 105±1754) which was then subcloned into the modified poliovirus cDNA between unique XhoI and SnaBI restriction sites (Fig. 1B) .
To determine that RNA from the replicon genomes encoding luciferase would replicate in transfected cells, RNA was transcribed in vitro from pT7-IC-Luc, as previously described . The RNA was then transfected into cells which had been previously infected for 2 h with VV-P1 at an m.o.i. of 10. After 6 h, the infected/transfected cells were metabolically labeled, and radiolabeled proteins were immunoprecipitated using anti-3D pol antibodies. Examination of protein expression resulted in the detection of the poliovirus 3CD protein (data not shown). We have shown previously that detection of 3CD by metabolic radiolabeling is indicative of RNA replication . High levels of luciferase enzyme activity were also detected from the transfected cells (data not shown).
Encapsidation of the replicon encoding luciferase
In previous studies, we have demonstrated that RNA from poliovirus-based replicon genomes could be encapsidated if transfected into cells previously infected with a recombinant vaccinia virus, VV-P1, which expresses the P1 protein Porter et al., 1993 Porter et al., , 1995 Porter et al., , 1996 Porter et al., , 1997 . Serial passage of encapsidated replicons in VV-P1-infected cells resulted in the generation of stocks of the encapsidated replicon. In order to generate a stock of encapsidated replicons encoding luciferase (referred to as vIC-Luc), RNA transcribed in vitro was transfected into cells infected with VV-P1; the replicon was subsequently serially passaged in the presence of VV-P1. An aliquot of each passage was used to infect HeLa H1 cells and the extracts were analyzed for luciferase activity (Fig. 2) . We found that the levels of luciferase activity from the transfected cells (passage 0) dropped (from 4, 119, 175 light units to approximately 231,450 light units) after one passage with VV-P1. By passage 2, an increase in the luciferase levels was detected from the infection of cells; by passages 3 and 4, the levels of luciferase detected in cells infected with encapsidated replicons had dramatically increased. We have further passaged this stock of encapsidated replicon for approximately 50 serial passages to derive a large scale stock suitable for further analysis.
Characterization of the encapsidated replicon encoding luciferase
To examine protein expression from the vIC-Luc encapsidated replicons, cells were infected with titered encapsidated replicon virus stock at an m.o.i. of 10 and metabolically labeled at 6 h postinfection (Fig. 3A) . Upon incubation of the cell lysates with anti-3D pol antibodies, a 72-kDa protein, which is consistent with the molecular mass of the poliovirus 3CD protein, was detected (Fig.  3A, lane 2) . Previous studies from this laboratory have shown that upon immunoprecipitation of radiolabeled proteins from poliovirus-infected cells with anti-3D pol antibody under similar labeling conditions, the 3CD protein is predominantly detected . We next wanted to characterize the luciferase protein expressed from the replicon. After incubation of replicon-infected cell lysates with anti-luciferase antibody, a protein with a molecular mass of approximately 70 kDa was detected, which is consistent with the size of the VP4-luciferase fusion protein (Fig. 3A , lane 4). We did not detect luciferase proteins of lower molecular mass, which might indicate deletions of the luciferase gene within the replicon after serial passage. Analysis of the replicon virion RNA by reverse transcription PCR indicated that the predominant DNA product amplified was the same size as the initial VP4-luciferase gene (data not shown).
Since previous studies have suggested that the luciferase enzyme is unstable in vivo (Andino et al., 1993) , we examined the stability of the luciferase fusion protein expressed in replicon-infected cells by pulse-chase analysis and immunoprecipitation using anti-luciferase antibodies (Fig. 3B ). For these studies, cells were infected with vIC-Luc at an m.o.i. of 10 and pulse-labeled for 30 min at 5 h postinfection. After pulse labeling,
Comparison of the levels of encapsidation after RNA transfection and serial passage with VV-P1. Cells infected with VV-P1 at an m.o.i. of 10 were transfected with RNA transcribed in vitro from the pT7-Luc replicon genome. Encapsidated replicons were harvested from the transfected cells and a portion was analyzed for luciferase activity as measured by light units (designated passage 0). The remainder was used for serial passages in cells which had been previously infected with VV-P1 at an m.o.i. of 10 (passages 1±4). A portion of the lysates from the each of the serial passages was used to infect cells for the analysis of luciferase activity as described under Materials and Methods.
complete medium was added for 0.5-, 1-, and 2-h chase periods. After the designated chase periods, infected cells were processed as described for immunoprecipitation with the anti-luciferase antibodies. A protein with a molecular mass consistent with that of the VP4-luciferase fusion protein (ϳ70 kDa) was detected from infected cells which were pulse-labeled. After incubation of the pulse-labeled cells in complete medium, decreasing amounts of the luciferase protein were detected as the chase times increased from 0.5 to 2 h (Fig. 3B , lanes 2±5); the amount of the luciferase fusion protein did decrease over time but was still detectable even after the 2-h chase period.
We next characterized the kinetics of protein expression from cells infected with the replicons encoding luciferase. For this experiment, equivalent amounts of cells were infected with vIC-Luc replicons at an m.o.i. of 10. Cells were also infected with another replicon, vICGag, which served as a negative control (Porter et al., 1993) . Infected cells were then harvested for standard luciferase enzyme assays as described under Materials and Methods at the time points indicated (Fig. 4A ). Luciferase activity was first detected at 4 h postinfection (measured in light units) from cells infected with vIC-Luc. The amount of detectable light units increased steadily and peaked at 12 h postinfection. Between 12 and 24 h postinfection, the number of light units detected from the cells infected with vIC-Luc declined steadily, which is probably a result of increasing cytopathic effects on the cells from the replicon infection. To determine if the enzymatic activity detected from lysates from cells infected with vIC-Luc replicons correlated with luciferase fusion protein expression, equivalent numbers of cells were infected at an m.o.i. of 10, metabolically labeled, and harvested for immunoprecipitation with anti-luciferase antibodies at various time points postinfection (Fig. 4B) . Consistent with the results from Fig. 4A , the luciferase fusion protein was first detected at 4 h postinfection (lane 3). The levels of luciferase fusion protein continued to increase until a maximum level was detected at 6 to 8 h postinfection (Fig. 4B, lanes 4 and 5) . These results are in contrast with the results in Fig. 4A , which shows the peak levels of luciferase enzyme activity at 12 h postinfection. These differences might be a result of a limitation of the anti-luciferase antibody react with all of the luciferase present in the samples. In other words, the immunoprecipitations were not quantitative, especially when the cell lysates contained large amounts of the VP4-luciferase present at later times postinfection.
To further characterize the encapsidated replicons which encode luciferase, we analyzed the correlation between the input virus and the measured light units following a defined time postinfection. Using a known quantity of the encapsidated replicon which encodes luciferase, we determined the relationship between the amount of virus (infectious units) and the measured light units following infection (Fig. 5) . We found a linear relationship between the input infectious units of replicons and the measured light units from cells infected with 0.01 to 1 infectious unit per cell (see inset graph). The limit of the level of sensitivity was at approximately 0.01 i.u. per cell.
trans encapsidation of replicons encoding luciferase
In a previous study, we have found that the replicon encoding HIV-1 gag could be trans-encapsidated when serially passaged with poliovirus type 1 (Porter et al., 1993) . To demonstrate the presence of the replicon within the stocks of poliovirus, we immunoprecipitated proteins from co-infected cells with antibody specific for the HIV-1 gag protein. However, detection of the replicon genome in the presence of the wild-type genome was complicated due to competition for radiolabel by both the replicon and wildtype RNAs resulting in a loss of sensitivity.
The use of the replicon encoding luciferase allows for a more sensitive assessment of replication in cells coinfected with different picornaviruses. For these studies, cells were co-infected with equivalent numbers of replicons encoding luciferase and poliovirus types 1, 2, or 3 (Sabin strains) (Fig. 6A) or related picornaviruses, bovine enterovirus, Coxsackievirus A21, Coxsackievirus B3, and enterovirus 70 (Fig. 6B) . The replication of the replicon was monitored by determination of luciferase activity 6 h after infection. From the examination of light units, we determined that the levels of luciferase activity in cells co-infected with vIC-Luc and type 1 poliovirus (Fig. 6A) or Coxsackievirus B3 (Fig. 6B) were reduced by approximately 30±50% from that of cells infected with replicons alone. In contrast, the expression of luciferase from the replicon in the presence of poliovirus types 2 and 3, bovine enterovirus, and Coxsackievirus A21 was enhanced at least 2-fold. Surprisingly, the level of luciferase activity in cells co-infected with replicons and enterovirus 70 was increased by approximately 10-fold over that of cells infected with replicon alone.
To determine whether the replicon could be encapsidated into virions following serial passage in the presence of a designated picornavirus, the replicons were co-infected with the viruses at equivalent moi (Fig. 7) . Following complete cell lysis, the lysate was harvested and used to reinfect cells. The next day, the infected cells were harvested; the cell lysate was designated as passage 1 (P1). This procedure was repeated for an additional serial passage to generate passage 2 (P2). Material from P1 and P2 was then used to infect cells which were assayed for luciferase activity. Passage of the replicon alone resulted in an approximate 30-fold drop in luciferase activity after the first passage (P1); by passage 2, the levels of luciferase activity from vIC-Luc replicons alone were barely detectable (approximately 100 light units (Figs. 7A and 7B) ). This result is consistent with the fact that the replicons do not encode their own capsid proteins and therefore undergo only one round of infection.
Upon co-infection of cells with vIC-Luc and poliovirus types 1, 2, or 3, luciferase activity was detected from each serial passage (Fig. 7A) . We observed a reduction of about 50% in the levels of luciferase activity from P1 to P2; the levels of activity though were still significantly higher than background levels, demonstrating that the replicons were trans-encapsidated upon passage with types 1 and 2 poliovirus. In contrast, the vIC-Luc passaged in the presence of poliovirus type 3 remained at high levels for each serial passage. Although the luciferase replicons are capable of competing with all three serotypes of poliovirus for capsid proteins, the replicons then appear to compete more efficiently for type 3 poliovirus capsids.
To determine if trans encapsidation of the poliovirus replicons would occur upon serial passage with different picornaviruses, we passaged vIC-Luc in the presence of Coxsackie A21 or B3 viruses, enterovirus 70, or bovine enterovirus (Fig. 7B) . After P2 of the replicons with the different enteroviruses, the luciferase activity was below the levels detected from the passage of replicons alone. These results demonstrate that although the replicons can replicate and express luciferase in cells co-infected with the different picornaviruses, a mechanism exists which excludes the replicons from trans encapsidation with the different picornaviruses.
DISCUSSION
In this report, we have described the construction and characterization of a replicon which encodes firefly luciferase protein. Transfection of cells with the replicon resulted in the expression of enzymatically active luciferase. The replicons were encapsidated in poliovirions FIG. 6 . Replication of the replicon encoding luciferase in cells co-infected with other picornaviruses. Cells were co-infected with vIC-Luc replicons and poliovirus type 1, 2, or 3 (A), or bovine enterovirus, enterovirus 70, Coxsackievirus A21, or Coxsackievirus B3 (B) at an equivalent m.o.i. of 10 for both the replicons and the different picornaviruses. At 6 h postinfection, the co-infected cells were processed for luciferase enzyme activity as described under Materials and Methods.
by cotransfecting into cells previously infected with VV-P1. Serial passage in the presence of VV-P1 resulted in the generation of stocks of the encapsidated replicon. Expression of luciferase protein correlated with the initial starting amount of the encapsidated luciferase replicon. The expression of luciferase from the replicon was decreased by co-infection of cells with type 1 poliovirus and Coxsackievirus B3; luciferase expression was increased in the presence of types 2 and 3 poliovirus, Coxsackievirus A21, bovine enterovirus, and enterovirus 70. The luciferase replicon could be encapsidated into poliovirus type 1, 2, and 3 virions, but not trans encapsidated into Coxsackieviruses A21 or B3, enterovirus 70, or bovine enterovirus.
The availability of an encapsidated replicon which expresses enzymatically active luciferase provides an important experimental tool for dissecting elements of poliovirus RNA replication and encapsidation. Previous studies have reported on the construction of poliovirus replicons which encode luciferase (Andino et al., 1993) . Consistent with our results, upon transfection into cells, the luciferase protein expressed from the replicon was enzymatically active and the levels correlated with replication of the genome. One difference between this study and the present study was FIG. 7 . trans encapsidation of replicon genomes encoding luciferase upon passage in cells co-infected with other picornaviruses. Cells were co-infected with vIC-Luc replicons and poliovirus type 1, 2, or 3 (A) or bovine enterovirus, enterovirus 70, Coxsackievirus A21, and Coxsackievirus B3 (B) at an equivalent m.o.i. of 10. The replicons were passaged with the wild-type picornaviruses for two successive passages. Cells were infected with material from each passage and processed for luciferase enzyme activity as described under Materials and Methods; P1, passage 1; P2, passage 2. that the luciferase protein was expressed as a fusion protein with the poliovirus VP4 protein. Interestingly, the expression of luciferase as a fusion protein did not drastically affect the enzymatic activity of the protein. To our knowledge, the expression of enzymatically active firefly luciferase as a fusion protein has not been reported. Previous studies using a replicon encoding luciferase protein which was not a fusion protein with the VP4 capsid sequences indicated that this enzyme was unstable in cells (Andino et al., 1993) . The results of our pulse±chase experiment, though, demonstrate that the enzyme is stable for at least 2 h (and possibly longer). It is possible that the VP4 protein stabilizes or protects the luciferase enzyme from degradation in the replicon-infected cells. Alternatively, since the VP4 protein retains the signal for myristylation, this could target the VP4-luciferase fusion protein to a different intracellular compartment than luciferase expressed without the VP4 protein. Additional studies using this replicon will be needed to resolve these possibilities.
Our study is unique since this is the first demonstration that replicons encoding luciferase protein can be encapsidated and, through serial passage with VV-P1, grown in quantities sufficient for studies of RNA replication and encapsidation. Indeed, we have passaged the encapsidated replicons described in the present study for over 50 serial passages in the presence of VV-P1 and found no deletion of the luciferase gene. Infection of cells with this replicon results in the synthesis of enzymatically active luciferase which can be detected from an infection initiated with as few as 0.01 i.u. in our culture system. Using the encapsidated replicons, we have determined that the kinetics of luciferase expression, as measured by an enzyme activity assay, parallels the infectious life cycle of poliovirus. These results extend our previous reports on the construction and characterization of replicons encoding foreign genes which relied on immunoprecipitation of the foreign protein using specific antibodies.
We have used the luciferase enzyme assay to characterize the trans encapsidation of the replicon in the presence of VV-P1. We found that the amount of encapsidated replicon RNA in the first passage after the initial transfection in the presence of VV-P1 was extremely low. However, after 4 serial passages, the levels of luciferase activity (and thus the amounts of encapsidated replicon) had increased to significant levels, which were comparable to those obtained from cells transfected with replicon RNA. Since the cells are infected with VV-P1 at a multiplicity of infection such that every cell is infected, the results of these studies suggest that the transfected replicon RNA, although competent for replication, does not interact with the encapsidation machinery as efficiently as RNA from the infection of cells with the encapsidated replicon. This could be due to subtle changes in the replicon RNA during replication such that only a subpopulation of the transfected RNA is competent for encapsidation. Therefore, the generation of encapsidated stocks of the replicon might then represent a selection of replicon RNAs which are efficiently encapsidated. Alternatively, it is possible that transfected RNA is localized to a different cellular compartment than the RNA which enters the cell via infection. While this difference does not affect RNA replication, it could influence subsequent encapsidation.
Early studies aimed at delineating the complexities of poliovirus RNA encapsidation have described the use of poliovirus DI genomes for investigating the specificity of encapsidation (Kajigaya et al., 1985) . In these studies, it was shown that DI genomes of poliovirus could be transencapsidated upon passage with poliovirus types 1, 2, and 3, but not with Coxsackievirus B1. Percy et al. (1992) have previously described chimeric poliovirus genomes containing the CAT gene which were encapsidated upon transfection into wild-type poliovirus-infected cells. However, the drawback to this approach for analysis of encapsidation is that the amount of RNA encoding CAT in the mixed virus stocks is dependent not only upon the efficiency of the transfection but also on the capacity of the CAT RNA to amplify in the presence of wild-type virus. In contrast, encapsidated replicons encoding luciferase allow for a more direct evaluation of RNA encapsidation by the poliovirus P1 capsid protein. In the present study, we found that the replicon encoding luciferase could be detected in each of the serial passages with poliovirus types 1, 2, or 3. We detected the highest levels of luciferase enzyme activity from the replicons passaged with type 3 poliovirus. The expression of luciferase from replicons in cells infected with either poliovirus type 1 or type 2 was lower than that in the presence of type 3 poliovirus, although still significantly above background. We do not think these differences are due to interference with the replication of the replicon RNA in the co-infected cells. In fact, luciferase expression was enhanced in cells co-infected with replicon and either type 2 or type 3 poliovirus. Our results, then, suggest that the replicons compete more efficiently for type 3 capsids than for type 1 or 2 capsids. If this is true, we would predict that a recombinant vaccinia virus encoding type 3 poliovirus capsid proteins should allow for higher encapsidation efficiency than a virus encoding type 1 poliovirus capsids. Experiments are ongoing to test this possibility.
Previous studies have suggested the possibility of trans encapsidation of poliovirus genomes into other picornavirus virions (Trautman and Sutmoller, 1971) . If this had occurred, it might have important consequences for the pathogenesis of poliovirus, as well as for picornaviruses in general. For example, immunization of infants that have a concurrent infection with another picornavirus (e.g., Coxsackie virus) with the poliovirus vaccine might result in trans encapsidation of the poliovirus genome into a Coxsackie virion which would not be neu-tralized by anti-poliovirus antibodies. Using the replicon genomes encoding luciferase, we examined the specificity of replicon RNA encapsidation upon passage with several different enteroviruses. We found that co-infection of cells with the luciferase replicon and Coxsackievirus A21 or enterovirus 70 resulted in an enhancement of luciferase activity. Even so, it was clear from analysis of the passage of the replicons with the different picornaviruses that trans encapsidation of the replicon RNA did not occur. Thus, although a common encapsidation signal exists between the three serotypes of poliovirus, it is distinct from that for Coxsackievirus A21 and B3, enterovirus 70, and bovine enterovirus. Although the specific encapsidation signal for poliovirus is at present unknown, one candidate which could be involved in encapsidation is the 5Ј genome-linked protein VPg. In support of this possibility, a previous study has identified mutations within the VPg coding region that resulted in RNA which replicated but did not produce infectious virus, suggesting that genomes with mutant VPg proteins were incapable of being encapsidated (Reuer et al., 1990) . Although VPg is covalently linked to both plus-and minus-strand RNA, previous studies have demonstrated that poliovirus RNA encapsidation is highly specific for plus-strand RNA, suggesting that encapsidation is also dependent upon signals specific for positive-sense RNA (Novak and Kirkegaard, 1991) . Thus, the encapsidation signal for poliovirus RNA is most likely a complex consisting of both RNA and protein determinants. The development of an encapsidated replicon encoding luciferase, as described in this study, provides an important experimental tool with which to now dissect the complexities of poliovirus RNA encapsidation.
MATERIALS AND METHODS
Tissue culture medium was purchased from Gibco/ BRL Company. The Tran 35 S-label (methionine and cysteine) and methionine-and cysteine-free Dulbecco's modified Eagle's medium (DMEM) were purchased from ICN Biochemicals. Synthetic DNA primers were purchased from Gibco/BRL. The luciferase assay kit was purchased from Promega.
Tissue culture cells and viruses
Cell monolayers of HeLa T4, BSC-40, or HeLa H1 cells (obtained from ATCC) were grown in DMEM supplemented with 10% fetal bovine serum (Porter et al., , 1996 . The recombinant vaccinia virus, VV-P1, which expresses the P1 capsid precursor protein in infected cells has been previously described (Ansardi et al., 1991; Morrow et al., , 1995 Morrow et al., , 1996a . Poliovirus types 1, 2, and 3 (Sabin strains) were obtained from Wyeth-Lederle, Vaccines. Coxsackie B3, Coxsackie A21, enterovirus 70, and bovine enterovirus were obtained from ATCC; viruses were grown and titered in HeLa H1 cells.
Construction of replicons containing the luciferase gene
To generate the replicons containing the luciferase gene, a modified version of the poliovirus cDNA, pT7-IC, was used . The replicon genome, pT7-ENV (825 aa)/VP4, contains the HIV-1 envelope gene substituted for the poliovirus VP2, VP3, and VP1 capsid genes (Anderson et al., 1996a,b) . This genome contains a unique XhoI restriction site at nucleotide 949, preceded by the VP4 capsid gene. The genome also contains a unique SnaBI restriction site at the 3Ј end of the P1 region at nucleotide 3359, followed by 8 amino acids encoding a cleavage site for the 2A protease (cleavage site underlined): Thr-LysAsp-Leu-Thr-Thr-Tyr-Gly.
To generate the replicon cDNA pT7-Luc, the luciferase gene (nucleotides 105±1754) was amplified from the plasmid pGEM-luc (Promega) using the following primers: 5Ј-CTC-GAG-GAA-GAC-GCC-AAA-AAC-ATA-AAG-3Ј and 5Ј-GTT-AAC-CAA-TTT-GGA-CTT-TCC-GCC-3Ј. The amplified DNA fragment contains a unique XhoI site at the 5Ј end and a HpaI site at the 3Ј end. The fragment was digested with XhoI and HpaI and ligated into the plasmid pT7-ENV (825 aa)/VP4 after digestion of the plasmid with XhoI and SnaBI. The resulting plasmid pT7-Luc, contains the complete gene encoding firefly luciferase positioned between nucleotides 949 and 3359, substituted in-frame for the VP2, VP3, and VP1 capsid genes of poliovirus.
Encapsidation of replicons
Previous studies from this laboratory have described the encapsidation and serial passage of replicon genomes containing foreign gene sequences using the recombinant vaccinia virus VV-P1 to provide P1 in trans (Porter et al., 1993 (Porter et al., , 1996 (Porter et al., , 1997 . To encapsidate the replicon RNA, HeLa T4 cells were infected with 5 PFU/ cell of VV-P1, which expresses the poliovirus capsid precursor protein P1 (Ansardi et al., 1991) . At 2 h postinfection, the cells were then transfected with RNA transcribed in vitro from the pT7-Luc replicon genome . The cultures were harvested and encapsidated replicons were collected by ultracentrifugation .
To generate virus stocks of encapsidated replicons encoding the luciferase protein, HeLa H1 cells were infected with 10±20 PFU/cell of VV-P1 for 2 h. The cells were then infected with lysate from the VV-P1-infected cells transfected with replicon RNA. The cells were harvested at 24 h postinfection and the supernatants, designated pass 1 (P1), were then stored at Ϫ70°C or used immediately for additional serial passages in the presence of VV-P1 .
Metabolic labeling and immunoprecipitation of viral proteins
In order to metabolically label proteins from infected/ transfected cells, the cultures were starved for methionine/cysteine, at the times indicated, by incubation in DMEM minus methionine/cysteine followed by the addition of Tran 35 S-label. For pulse±chase analysis, complete medium was added to infected cells after labeling with Tran 35 S-label, and infections were harvested at the indicated time points. Infected cells were processed for radioimmunoprecipitation as previously described and incubated with the appropriate antibodies . The immunoprecipitates were collected after the addition of protein A±Sepharose and analyzed by SDS± polyacrylamide gel electrophoresis as previously described .
Estimation of virus titers of encapsidated replicon virus stocks
Encapsidated replicons do not encode their own capsid proteins and thus cannot form plaques on cell monolayers. To determine the virus titers of encapsidated replicons encoding luciferase, cells were infected with serial dilutions of the encapsidated replicon virus stocks; similar amounts of cells were infected with specific amounts of type 1 Mahoney poliovirus (as determined by plaque assay). At 5 h postinfection, cells were metabolically labeled, and specific viral proteins were immunoprecipitated with anti-3D pol antibodies. After separation of proteins by SDS±PAGE, the gels were subjected to phosphorimagery to quantitate the radioactivity in each sample. A standard curve was generated from the quantitation of protein expressed from known amounts (plaque-forming units) of type 1 Mahoney poliovirus. The values obtained from the quantitation of protein expressed from the luciferase replicons were then plotted on the poliovirus standard curve to estimate the titer. In previous studies, we have shown that the titer of the encapsidated replicon virus stocks, referred to as infectious units (i.u.), correlated with plaque-forming units from wild-type poliovirus .
Luciferase assays
For luciferase assays, equivalent amounts of cells were infected with titered virus stocks of encapsidated replicons with designated moi. At 5±7 h postinfection, the culture medium was removed, and the infected cells were washed 2ϫ with PBS (phosphate-buffered saline). The cells were then scraped from the tissue culture dishes, resuspended in 1 ml PBS, and pelleted at 14,000g for 2 min at room temperature. After discarding the supernatant, the cell pellets were used for assays immediately or stored at Ϫ70°C. For assays, the cell pellets were resuspended in 100 l 1ϫ lysis buffer [25 mM Tris±phosphate, pH 7.8, 2 mM DTT (dithiothreitol), 2 mM DCTA (1, 2 diaminocyclohexane-N,N,NЈ,NЈ-tetraacetic acid), 10% glycerol, and 1% Triton X-100] and incubated at room temperature for 10 min. In a separate tube, 10 l of the room-temperature cell lysate was mixed with 100 l of the luciferase assay reagent (20 mM tricine, 1.07 mM (MgCO 3 ) 4 Mg(OH) 2 ⅐ 5 H 2 O, 2.67 mM MgSO 4 , 0. 1 mM EDTA, 33.3 mM DTT, 270 M coenzyme A, 470 M luciferin, 530 M ATP, pH 7.8), and 50 l of the mixture was assayed for light detection using a luminometer (Monolight 2010, Analytical Luminescence Laboratories). The data are presented as relative light units.
Co-infection of cells with replicons and other picornaviruses
Cells were co-infected with the encapsidated replicons encoding luciferase and designated picornaviruses at an equivalent m.o.i. of 10. Viruses were allowed to adsorb for 1 h at 37°C. The inoculum was then removed and replaced with complete medium. The infection was allowed to proceed for 6 h, at which time cells were processed for luciferase assays. For the encapsidation experiments, the co-infected cultures were incubated for 24 h, at which time a complete cytopathic effect had occurred. Following three freeze±thaw cycles and removal of cell debris, one-half of the supernatant was used to reinfect cells; the other half was stored at Ϫ70°C. After a 1-h adsorption, the inoculum was removed and the infection continued for an additional 24 h. The cultures were processed as before and repassaged on cells for a total of two passages. After two serial passages, cells were infected for 6 h with material from each passage and processed for luciferase assays.
